A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...
Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
